
GLP-1 Weight-Loss Drugs May Lower Cancer Recurrence by Boosting Immune Response, Expert Says
The American Association for Cancer Research's 2026 report notes that obesity is a major cancer risk factor, prompting interest in whether GLP-1 drugs like Ozempic and Mounjaro can reduce cancer incidence. While retrospective studies suggest lower cancer risk and higher survival rates for GLP-1 users, evidence remains mixed, with some studies showing increased risks for specific cancers like thyroid cancer. Dr. Sai Yendamuri of Roswell Park Comprehensive Cancer Center suggests these drugs may alter the body's immune response to fight cancer cells, potentially lowering recurrence rates in lung cancer and melanoma. However, randomized clinical trials are lacking, and it remains unclear if benefits stem from weight loss or direct immune effects. Future trials will determine if GLP-1s can serve as a preventive mechanism for cancer.













